ELPA-HepC_B

0

In addition, the use of Sinfonia, the regional Covid screening system, is being evaluated. At the same time, we plan to recover what has already been done in the SerDs and prisons of numerous provinces, such as the ad hoc programs carried out in the structures of Salerno and Caserta. Now we need to take what until now have been only pilot projects and turn them into a ‘system’.

So far we have found that around 40% of SerD patients are positive and half of them do not know they are. In the prison population about 10-13% are infected and even here about half ignore it. It is often not easy for these populations to access treatment “.

HEPATITES DELTA AND E

To complete the picture of Hepatitis, there are Delta and E. The hepatitis D virus to infect liver cells requires in particular the help of the hepatitis B virus, so the infection occurs in subjects also affected by HBV. Preventive measures are similar to HBV prophylaxis: the hepatitis B vaccine is also able to protect against hepatitis D.

Hepatitis E is also an acute viral disease, generally self-limiting and very rarely subject to chronicization , with clinical characteristics similar to those of Hepatitis A. It is estimated that 1/3 of the world population has been exposed to the virus and that every year 20 million people acquire the infection, with at least 600,000 deaths each year.

In Italy, in the years 2007-2018 there was a continuous increase in the number of cases of Hepatitis E reported in Seieva, with a peak in 2019, a year in which the number of cases doubled compared to the previous year (98 cases compared to 49 in 2018). During 2020, only 24 cases were reported, with a decrease in line with other types of Hepatitis and probably correlated with the pandemic state.

As every year, July 28 is World Hepatitis Day, promoted by the World Health Organization (WHO) for the dissemination of information useful for the prevention, diagnosis and treatment of chronic viral hepatitis.

In Italy, chronic viral hepatitis has been the main cause of chronic liver disease and cirrhosis in the general population for many years; the recent development of antiviral therapies effective in eliminating (hepatitis C; HCV) or suppressing (hepatitis B; HBV) the viruses responsible for these diseases has made it possible to progressively reduce the incidence of cirrhosis and its clinical complications

(liver cancer and organ failure), including the need for transplantation.But what is it about? We met Pietro Lampertico, Director of Gastroenterology and Hepatology at the Polyclinic of Milan and Roberta D’Ambrosio, a gastroenterologist expert in liver pathology.

LEAVE A REPLY

Please enter your comment!
Please enter your name here